Differences in Pain, Happiness, and Global Functioning Scores in Patients with OI Between Pamidronate and Zoledronate by Sekeramayi, Tinotenda et al.
University of Nebraska Medical Center 
DigitalCommons@UNMC 
EMET Posters College of Medicine Students 
2021 
Differences in Pain, Happiness, and Global Functioning Scores in 





Follow this and additional works at: https://digitalcommons.unmc.edu/emet_posters 
 Part of the Medical Education Commons 
Differences in pain, happiness, and global functioning 
scores in patients with OI between pamidronate and 
zoledronate
Tinotenda Sekeramayi, BS, Elizabeth Strudthoff, RN, BSN, Kaeli Samson, MA, MPH, Maegen Wallace, MD
University of Nebraska Medical Center, Omaha, NE; 
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Osteogenesis imperfecta (OI) is a heritable skeletal dysplasia that affects approximately 1 in 10,000-
20,000 births (Lim et al., 2017). Approximately ninety percent of OI cases are due to Type I collagen 
mutations. The disorder is broken down into types, with Type I-IV being autosomal dominant and Type VI-
XIII being autosomal recessive. Bisphosphonates, particularly pamidronate and zoledronate, are the 
mainstay treatment of the symptoms of OI. At many institutions, the choice of whether to prescribe 
pamidronate or zoledronate is largely dependent upon the provider and patient comfort (Garganta et al., 
2018). Bisphosphonate therapy is typically initiated in mild to moderately severe patients when children 
with OI have two fragility fractures per year (Garganta et al., 2018). Current studies demonstrate that 
bisphosphonate therapy relieves bone pain acutely following infusion in children with OI but stop short of 
commenting on the duration of the relief and if there is any long-term reduction in pain. Although long-bone 
fractures still occur in moderate or severely affected patients on bisphosphonate therapy, IV 
bisphosphonate treatment can improve mobility, especially when started early in life (Dwan et al., 2016). 
However, the current literature lacks studies that investigate the global functional status of children on 
long-term IV bisphosphonate therapy, both as a snapshot in time and longitudinally as the children 
mature.
The purpose of this study is to provide a snapshot of happiness, comfort, and global functioning scores of 
a population of pediatric patients with Type III or Type IV Osteogenesis Imperfecta on long-term IV 
bisphosphonate therapy, namely pamidronate and zoledronate. In addition, this study will investigate 
whether those scores are significantly increased for patients on pamidronate versus those on zoledronate 
therapy.
Analytical Methods
Critical data includes: OI type, gender, drug, dose, age of first infusion, 
frequency of dose, parent- reported Pediatric Outcomes Data Collection 
Instrument [PODCI] data: pain scores, comfort scores, happiness scores, 
global functioning scales
The treatment noted on the visit closest to when a patient was 11 years of age 
was determined. The closest visit for each patient was only included if the 
patient was within +/- 2 years of 11 years of age on their treatment note date. 
PODCI data associated with a visit that was closest to the treatment note date, 
but had to be within +/- 1 years of the treatment note date, was linked to the 
treatment data.
Descriptive statistics for PODCI scores are given as medians and interquartile 
ranges (IQRs, representing the range of the middle 50% of the data). Wilcoxon 
Rank Sum tests were used to examine differences in PODCI scores between 
treatment groups. All analyses were performed using SAS software version 9.4 
(SAS Institute Inc., Cary, NC).
Pain Scores
There was a significant difference in global functioning scores between 
patients on pamidronate and zoledronate but not at the p=0.05 level; there 
was a p-value of 0.0828. 
Global Functioning
For patients around 10 years old, those who were on zoledronate had 
statistically higher pain scores than those on pamidronate, with a p-value 
of 0.0085.
Happiness
There was no statistically significant difference in happiness scores 
compared to those on zoledronate, with a p-value of 0.4634.
Conclusion and Future Directions
• Our study begins to explore differences in pain, happiness, and 
global functioning as measured in PODCI between the 
pamidronate and zoledrone in a small sample of 11 year old 
patients with type III or type IV OI. 
• There are a statistically significant higher pain scores in patients 
taking zoledronate compared those on pamidronate. 
• However, since this was not a randomized control trial, we cannot 
say that zoledronate caused pain as most patients begun their 
bisphosphonate therapy on pamidronate and switched to 
zoledronate for reasons such as increased pain, fractures, or 
decreased in bone mineral density (BMD). 
• From a statistical standpoint, we cannot conclude that they are 
both good, rather, we didn’t find evidence that one was 
superior/inferior to the other.
• Limitations of our study include small sample size, 
nonrandomized control trials, and the patients on zoledronate had 
started treatment on pamidronate. Future studies are needed to 
further assess patient reported psychological and global 
functioning outcomes in OI. 
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Introduction
Hypothesis
The long-term use of pamidronate over zoledronate is associated with lower pain 
scores and higher happiness scores and global functioning scores in patient with Type 
III or Type IV OI. 
Drug N Median IQR
Pamidronate 20 56.1 50.8;71.9
Zoledronate 6 86.1 75.6;93.3
Drug N Median IQR
Pamidronate 20 61 53.2;76.8
Zoledronate 6 79.9 71;86.5
Drug N Median IQR
Pamidronate 20 75 50;95
Zoledronate 6 65 55;80
